Human Interferon-alpha2b (Highly Pure)

<strong>Human Interferon-alpha2b (Highly Pure)</strong>_x000D_ <strong>Catalog number:</strong> B2010283_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 10 ug_x000D_ <strong>pH:</strong> 7.4 upon reconstitution_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Appearance:</strong> Powder_x000D_ <strong>Applications:</strong> highly pure Human Interferon-alpha2b (Highly Pure) expressed in HEK 293 cells. This protein acts as a regulatory mediator of the immune response with established antiviral and antitumor activities._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> rHuIFN-α2b; IFNA; INFA2; IFN-a 2b_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T._x000D_ Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C_x000D_ virus-associated hepatocellular carcinoma is capable of improving hepatic_x000D_ functional reserve and survival. Hepatogastroenterology. 2012 Mar-_x000D_ Apr;59(114):529-32._x000D_ _x000D_ 2: Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and_x000D_ human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009_x000D_ Apr;25(4):991-1002._x000D_ _x000D_ 3: Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D,_x000D_ Bernasconi P, Mancini M, Donti E, Grignani F, et al. Interferon alpha-2b as_x000D_ therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients_x000D_ treated with intermittent or daily administration. Blood. 1988 Aug;72(2):642-7._x000D_ _x000D_ 4: Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG._x000D_ Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic_x000D_ hepatitis C. Nat Biotechnol. 2007 Dec;25(12):1411-9._x000D_ _x000D_ 5: Umemoto S, Haruta M, Sakisaka M, Ikeda T, Tsukamoto H, Komohara Y, Takeya M,_x000D_ Nishimura Y, Senju S. Cancer therapy with major histocompatibility complex-_x000D_ deficient and interferon β-producing myeloid cells derived from allogeneic_x000D_ embryonic stem cells. Cancer Sci. 2019 Oct;110(10):3027-3037._x000D_ _x000D_ 6: Aruna, Li L. Anti-Interferon Alpha Antibodies in Patients with High-Risk_x000D_ BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human_x000D_ Interferon-α. Med Sci Monit. 2018 Apr 17;24:2302-2309._x000D_ _x000D_ 7: Mitchell MS. Immunotherapy as part of combinations for the treatment of_x000D_ cancer. Int Immunopharmacol. 2003 Aug;3(8):1051-9._x000D_ _x000D_ 8: Kumar L, Gangadharan VP, Rao DR, Saikia T, Shah S, Malhotra H, Bapsy PP,_x000D_ Singh K, Rao R. Safety and efficacy of an indigenous recombinant interferon-_x000D_ alpha-2b in patients with chronic myelogenous leukaemia: results of a_x000D_ multicentre trial from India. Natl Med J India. 2005 Mar-Apr;18(2):66-70._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/2621318/">_x000D_ 9: Lagra F, Raptopoulou-Gigi M, Orphanou-Koumerkeridou H, Goulis G. In vitro_x000D_ effect of interferon alpha-2b on T lymphocyte transformation and leukocyte_x000D_ migration inhibition in patients with chronic brucellosis. Immunopharmacol_x000D_ Immunotoxicol. 1989;11(2-3):223-32. </a>_x000D_ _x000D_ <strong>Products Related to Human Interferon-alpha2b (Highlly Pure) </strong> <a href="https://moleculardepot.com/product-category/Proteins/">: Proteins</a>